| TAH Drug Code | OIRE |
|---|---|
| Indications | Treatment of patients with locally advanced or metastatic adenocarcinoma of the lung who have previously received chemotherapy. |
| Dosing | 250 mg orally once daily with or without food. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Patients with known severe hypersensitivity to gefinitib or to any of the excipients of Iressa. |
| Adverse Effects | Diarrhoea, nausea, skin rash, dry skin, vomiting, anorexia, stomatitis, liver function abnormalities, nail disorder, alopecia, asthenia, conjunctivitis & blepharitis. Dermatologic: Acne (25% to 33% ), Dry skin (13% to 26% ), Pruritus (8% to 9% ), Rash (43% to 54% ) Endocrine metabolic: Weight loss (3% to 5% ) Gastrointestinal: Diarrhea (48% to 67% ), Loss of appetite (7% to 10% ), Nausea (13% to 18% ), Vomiting (9% to 12% ) Neurologic: Asthenia (4% to 6% ) |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Risk |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |